TransCode Therapeutics Inc. (RNAZ) announced the pricing of a public offering of 10 million shares of its common stock at a public offering price of $0.30 per share, for expected gross proceeds of $3 million, before deducting placement agent commissions and offering expenses.
The offering is expected to close on July 24, 2024, subject to satisfaction of customary closing conditions.
The company plans to use the net proceeds from the offering primarily for product development activities, including one or more clinical trials with TTX-MC138, its lead therapeutic candidate, and related investigational new drug (IND) enabling studies, and for working capital and other general corporate purposes.
ThinkEquity is acting as the sole placement agent for the offering.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.